Forte Capital LLC ADV Purchases 11,576 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Forte Capital LLC ADV raised its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1,852.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,201 shares of the pharmaceutical company’s stock after acquiring an additional 11,576 shares during the quarter. Forte Capital LLC ADV’s holdings in Vertex Pharmaceuticals were worth $5,674,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of VRTX. Norden Group LLC boosted its position in Vertex Pharmaceuticals by 61.3% during the first quarter. Norden Group LLC now owns 992 shares of the pharmaceutical company’s stock valued at $415,000 after acquiring an additional 377 shares during the last quarter. Quent Capital LLC boosted its position in Vertex Pharmaceuticals by 33.0% during the first quarter. Quent Capital LLC now owns 399 shares of the pharmaceutical company’s stock valued at $167,000 after acquiring an additional 99 shares during the last quarter. Larson Financial Group LLC boosted its position in Vertex Pharmaceuticals by 714.3% during the first quarter. Larson Financial Group LLC now owns 228 shares of the pharmaceutical company’s stock valued at $95,000 after acquiring an additional 200 shares during the last quarter. Advisory Alpha LLC bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth about $356,000. Finally, Advisory Services Network LLC boosted its position in shares of Vertex Pharmaceuticals by 31.7% during the 1st quarter. Advisory Services Network LLC now owns 9,751 shares of the pharmaceutical company’s stock worth $4,076,000 after purchasing an additional 2,348 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the transaction, the chairman now owns 9,994 shares in the company, valued at $4,987,006. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the transaction, the chairman now owns 9,994 shares in the company, valued at approximately $4,987,006. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now directly owns 4,435 shares in the company, valued at $2,217,500. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Trading Down 1.2 %

Shares of VRTX stock opened at $493.64 on Thursday. The company has a 50 day moving average of $474.81 and a 200-day moving average of $466.95. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 12-month low of $341.90 and a 12-month high of $510.64. The firm has a market cap of $127.41 billion, a P/E ratio of -248.06 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.88%. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same period last year, the firm earned $3.67 EPS. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of research analyst reports. UBS Group increased their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday. Canaccord Genuity Group increased their price objective on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $600.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, October 21st. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Finally, Barclays cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $472.00 to $509.00 in a research report on Monday, August 5th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $495.96.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.